Stock Market & Financial Investment News

Mallinckrodt announces settlement of Ofirmev injection patent litigationMallinckrodt announced that its subsidiary, Cadence Pharmaceuticals, has entered into settlement and license agreements with Fresenius Kabi USA resolving pending patent litigation involving Ofirmev injection. The companies are not disclosing specific terms of the settlement and license agreements, except that Cadence has granted Fresenius Kabi a non-exclusive right to market an intravenous acetaminophen product in the U.S. under Fresenius Kabiís NDA on December 6, 2020, or earlier under certain circumstances. Mallinckrodtís subsidiary Cadence has two patents covering Ofirmev listed in the Orange Book, the last of which will expire on June 6, 2021. Cadence had filed suit against Fresenius Kabi in January 2013.